The leading global conference for Health Economics and Outcomes Research (HEOR).
Meet us November 6-9, 2022
Austria Center Vienna
Bruno-Kreisky-Platz 1, Vienna
Won Chan Lee and Jennifer Ken-Opurum will represent Axtria at ISPOR Europe 2022 from 6-9 November in Vienna, Austria. This is an in-person and virtual event for HEOR experts and thought leaders from all over the globe to discuss growth opportunities for health systems, patients, and technology developers. Won Chan Lee and Jennifer Ken-Opurum will make the following poster presentations at the event.
Won Chan Lee, Ph.D.
Principal and Head, RWE/HEOR, Axtria
Dr. Lee has more than 17 years of experience in health economics and outcomes research (HEOR) including strategic planning, economic modelling, RWE database studies, post-marketing studies, HRQL/PRO assessments, HEOR roadmap, value proposition development, HTA assessment, publication strategies, etc. He serves as RWE/HEOR practice lead and principal at Axtria. Dr. Lee holds a PhD in Health Economics from the Graduate Centre of the City University, New York and a master’s degree in Economics from the University of Grenoble, France.
Jennifer Ken-Opurum, Ph.D.
Associate Director, RWE/HEOR, Axtria
Dr. Ken Opurum is an experienced consultant and RWE researcher providing solutions to key business problems for clients in the pharma and biotech domain. Dr. Ken-Opurum has been responsible for providing strategic insights and leading teams of research analysts and data scientists on secondary database analysis, primary patient / stakeholder surveys, patient chart revies, prospective cohort studies, etc. Dr. Ken-Opurum holds a PhD in Nutrition Science and Bachelor of Science in Dietetics from Purdue University, USA.
Monday, November 7, 2022
15:00 to 18:15 (CET)
Ken-Opurum J, Vadagam P, Srinivas SSS, Faith L, Preblick R, Park S, Charland S, Revel A
The objective of this study was to evaluate the economic benefits of anti-arrhythmic drugs (AADs) in comparison with ablation from a US payer perspective. A Rhythm Control Economic model was used to compare different treatment scenarios assess the economic benefits of AADs (dronedarone, amiodarone, sotalol, flecainide, propafenone, dofetilide, and AADs as a group) vs ablation. The results of the study bring forward interesting insights in comparison of direct and combination therapies.
Tuesday, November 8, 2022
15:00 to 18:15 (CET)
Ponomareva E, Siegfried C, Srinivas SSS, Preblick R, Park S, Wilson L, Revel A
This study incorporates real-world evidence (RWE) in a value-based budget impact model (BIM) to demonstrate the value and affordability of Gla-300 for the treatment of adult patients with type 2 diabetes mellitus (T2DM) receiving basal insulins (Bis) from a U.S. payer perspective. A prevalence-based modelling approach was employed, consisting of three types of patients receiving BIs: prevalent patients (have been on insulin treatment for at least one year), naïve patients (new to the BI treatment, less than one year), switchers (previously naïve or prevalent patients who have switched insulin treatments). The model assessed the cost of treatment (drug costs), hypoglycemic events (associated with emergency, inpatient, and outpatient visits), and diabetes-related healthcare resource utilization (HCRU) costs (associated with emergency, inpatient, and outpatient visits). The study presented base case results by patient population, type in different scenarios.
Please contact Won Chan Lee and Chet Baboor at connect@axtria.com.
Axtria SalesIQTM is the leading sales planning and operations solution for the global life sciences industry that enables effective and motivated sales teams resulting in higher commercial success.
Axtria InsightsMAxTM is a cloud-based, unified analytics product built for the Life Sciences industry, with a rich reusable library of data preparation capabilities and analytics models across sales, marketing, payer, patient, and trade domains.
Axtria CustomerIQTM is the most advanced next best action-driven customer engagement solution for life sciences that formulates effective omnichannel interactions for customers to optimize commercial activity.
Copyright © 2023 Axtria. All Rights Reserved.
Axtria Cookie Policy & Privacy Statement.